267405-16-3Relevant academic research and scientific papers
Benzamide derivatives as blockers of Kv1.3 ion channel
Miao, Shouwu,Bao, Jianming,Garcia, Maria L.,Goulet, Joung L.,Hong, Xingfang J.,Kaczorowski, Gregory J.,Kayser, Frank,Koo, Gloria C.,Kotliar, Andrew,Schmalhofer, William A.,Shah, Kashmira,Sinclair, Peter J.,Slaughter, Robert S.,Springer, Marty S.,Staruch, Mary Jo,Tsou, Nancy N.,Wong, Frederick,Parsons, William H.,Rupprecht, Kathleen M.
, p. 1161 - 1164 (2003)
The voltage-gated potassium channel, Kv1.3, is present in human T-lymphocytes. Blockade of Kv1.3 results in T-cell depolarization, inhibition of T-cell activation, and attenuation of immune responses in vivo. A class of benzamide Kv1.3 channel inhibitors
Pseudosaccharin amines as potent and selective KV1.5 blockers
Lloyd, John,Finlay, Heather J.,Kover, Alexander,Johnson, James,Pi, Zulan,Jiang, Ji,Neels, James,Cavallaro, Cullen,Wexler, Ruth,Conder, Mary Lee,Shi, Hong,Li, Danshi,Sun, Huabin,Chimalakonda, Anjaneya,Huang, Christine,Salvati, Mark,Levesque, Paul
, p. 4983 - 4986 (2015)
Phenethyl aminoheterocycles like compound 1 were known to be potent IKur blockers although they lacked potency in vivo. Modification of the heterocycle led to the design and synthesis of pseudosaccharin amines. Compounds such as 14, 17d and 21c were found to be potent KV1.5 blockers and selective over other cardiac ion channels. These compounds had potent pharmacodynamic activity, however, they also showed off-target activities such as hemodynamic effects.
Carbocyclic potassium channel inhibitors
-
, (2008/06/13)
The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
